Biogen secures accelerated approval for Alzheimer's drug

Within 6 months of the new FDA commissioner's appointment, Biogen will receive accelerated approval for its Alzheimer's drug candidate. The regulatory shift under the new leadership will favor breakthrough therapies.

Implied probability (Yes)

55%